Alan Foster

Alan Foster

Company: Otonomy

Job title: Vice President of Research


Gene Replacement Therapy for GJB2-Related Hearing Loss 1:15 pm

• Review of GJB2 gene mutations, the most common cause of congenital hearing loss • Development of OTO-825 for GJB2 gene therapy • Preclinical proof-of-concept: OTO-825 rescues cochlear morphology and hearing functionRead more

day: Post Conference Day

Optimizing Clinical Outcomes through an Effective Drug Delivery Approach 9:00 am

• Successful technologies for otic drug delivery • How to successfully translate PK studies in animals to an optimal dosing paradigm in human clinical trials • What drug delivery factors are important to patients, physicians and payors? • What lessons cam be learned from drug delivery for other conditions including ocular disorders?Read more

day: Day Two

Panel Discussion: Looking Beyond 2022 – Future Directions for Inner Ear Therapeutics 9:00 am

• Showcasing the future directions in inner ear therapeutics from industry, what are the latest innovations happening in the space in the next 5 years? • What are the key milestones companies are trying to achieve in 2022/2023 and beyond? • What are the challenges to come post-regulatory?Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.